Next Article in Journal
Not All Canadian Cancer Patients Are Equal—Disparities in Public Cancer Drug Funding across Canada
Previous Article in Journal
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
 
 
Commentary

Article Versions Notes

Curr. Oncol. 2022, 29(3), 2046-2063; https://doi.org/10.3390/curroncol29030165
Action Date Notes Link
article xml file uploaded 17 March 2022 13:10 CET Original file -
article xml uploaded. 17 March 2022 13:10 CET Update https://www.mdpi.com/1718-7729/29/3/165/xml
article pdf uploaded. 17 March 2022 13:10 CET Version of Record https://www.mdpi.com/1718-7729/29/3/165/pdf
article supplementary file uploaded. 17 March 2022 13:10 CET - https://www.mdpi.com/1718-7729/29/3/165#supplementary
article html file updated 17 March 2022 13:11 CET Original file -
article html file updated 1 August 2022 06:12 CEST Update https://www.mdpi.com/1718-7729/29/3/165/html
Back to TopTop